SCHEMBL5050574

SCHEMBL5050574

NC(=O)NS(=O)(=O)c1cccc(N)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.61
PRSS1 P07477 3/20 0.61
PRSS2 P07478 3/20 0.61
PRSS3 P35030 3/20 0.61
ALDH1A1 P00352 2/20 0.56
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
POLB P06746 2/20 0.56
LMNA P02545 1/20 0.55
CA2 P00918 2/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA4 P22748 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
CYP19A1 P11511 1/20 0.53
PKM P14618 2/20 0.51
FBP1 P09467 1/20 0.51
KAT6A Q92794 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6297904 0.84 TSHR (0.64) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL27714135 0.81 FBP1 (0.61) ALDH1A1FBP1KMT2A
SCHEMBL18028832 0.81 KAT6A (0.51) TSHRPOLBLMNAKAT6AHTR6
SCHEMBL8549266 0.80 F2 (0.51) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL8589883 0.80 ALDH1A1 (0.67) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL23918994 0.80 LMNA (0.65) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL6158564 0.80 MEN1 (0.69) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL15054822 0.80 F2 (0.51) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL9302922 0.80 F2 (0.51) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL370189 0.79 CA2 (0.56) LMNACA2CA1CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114437062-B Compound capable of being used as sodium channel regulator and application thereof 成都海博为药业有限公司 2024-05-17 CN disclosed
CN-114437062-A Compound capable of being used as sodium channel regulator and application thereof 成都海博为药业有限公司 2022-05-06 CN disclosed
EP-1888045-A2 ORAL PHARMACEUTICAL COMPOSITION FOR TREATING A COX-2 MEDIATED CONDITION FLAMEL TECHNOLOGIE, Société Anonyme (FR) 2008-02-20 EP disclosed
WO-2007036809-A2 NOVEL ACETYLSALICYLIC ACID FORMULATIONS FLAMEL TECHNOLOGIES S.A. (US) 2007-04-05 WO disclosed
EP-1551403-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA Arena Pharmaceuticals, Inc. (US) 2005-07-13 EP disclosed
WO-2004032928-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA ARENA PHARMACEUTICALS, INC. (US) 2004-04-22 WO disclosed